In a move that underscores growing momentum in telehealth, Fellos, a digital clinic focused on men’s health, has raised approximately €2.15 million in growth capital. The funding round drew in a cohort of strategic backers, including healthcare professionals, Dutch Operator Fund, and Capital Mills, propelling Fellos further on its mission to make essential men’s health services more accessible.
The company and its offering
Founded in 2024 by Sibren Tolsma and Rob Smeitink, Fellos is designed to serve men who might hesitate to approach traditional clinicians for sensitive health issues. The platform provides consultations with Dutch BIG‑registered doctors, prescription services via partner pharmacies, and discreet medication delivery. Among its core treatment areas are:
Sexual health (erectile dysfunction, premature ejaculation)
Skin conditions such as acne
Hair loss, including genetic hairline recession treated with combinations like finasteride and minoxidil
Since launch, Fellos has already treated over 10,000 patients. The current funding round enables the company to extend its healthcare services and deepen its reach.
Key investors & the funding context
Dutch Operator Fund I, a fund focused on tech‑driven Netherlands‑based startups in pre‑seed and seed stages, is one of the anchor investors. It typically invests between €75,000 and €200,000, with follow‑on funding options.
Capital Mills and a group of medical practitioners also joined this round. The investor mix suggests both financial and domain expertise backing Fellos.
Prior to this, Fellos had secured €650,000 in a pre‑seed round earlier in 2025.
What the founders say
“With Fellos, we want to lower the barriers for men to access healthcare,” say founders Sibren Tolsma and Rob Smeitink. “We see that men often wait too long — and unnecessarily — before addressing their symptoms. Our digital approach makes it easier to take the first step toward a solution. This investment enables us to launch new care areas and broaden our mission.”
Medical investor Harry van den Brink adds: “I support Fellos’ mission and see the demand for online healthcare growing rapidly. Through Fellos, we offer a valuable addition to the current healthcare landscape and make care more accessible. With my medical background, I hope to make a meaningful contribution.”
How it works & user experience
Fellos’ care model is designed for ease and discretion. Key features:
Users fill out an online intake questionnaire that takes just a few minutes.
Within about 48 hours, a BIG‑registered doctor diagnoses and prescribes a treatment plan.
If the patient is suitable, medication is delivered via a Dutch partner pharmacy in discreet, unmarked packaging. Refill or follow‑up consultations are supported through chat or video.
The cost structure: there is a medical intake fee (≈ €14.95) and then charges for the treatment itself. If someone is deemed unsuitable, they get a full refund.
Challenges & competitive landscape
Though digital health has broad potential, Fellos must navigate regulatory expectations tightly. Medications must comply with European Medicines Agency (EMA) or Dutch regulatory standards. Ensuring safety and managing interactions is non‑negotiable.
Competing platforms already exist or are emerging across Europe addressing telehealth, men’s sexual health, dermatology, etc. Fellos’ ability to maintain quality, build trust, preserve privacy, and scale efficiently will be critical.
Editorial perspective: Market dynamics and what lies ahead
Telehealth for men’s health is moving from margin to mainstream. The stigmas around issues like erectile dysfunction, premature ejaculation, or alopecia are slowly giving way, aided by online platforms that promise anonymity, speed, and convenience. Fellos is playing into this shift by packaging “deep care” into a low‑barrier‑entry model, particularly in a country like the Netherlands, which has strong regulatory oversight and comparatively high digital readiness.
What makes this round notable is not just the money, but the investor mix: medical professionals, strategic funds with domain focus, and capital that expects both usability and clinical legitimacy. If Fellos can scale to its ambition of “one million people across Europe by 2030” (a target they have stated previously) without diluting its clinical standards, it could become a blueprint for similar ventures in larger European markets.
Still, the next frontier will test them: expanding into new care verticals (e.g. mental health, chronic conditions), navigating cross‑border licensing, reimbursement by insurers, and optimizing for cost vs. quality. With the current capital, Fellos is well‑positioned to accelerate. Whether it becomes a dominion or one among many in digital men’s health depends on execution.
If you need further assistance or have any corrections, please reach out to editor@thetimesmag.com.
